학술논문

A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP).
Document Type
Academic Journal
Author
Starkey T; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.; Ionescu MC; UK Health Security Agency, London, UK.; Tilby M; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Little M; Oxford University Hospitals NHS Trust, Oxford, UK.; Burke E; Oxford University Hospitals NHS Trust, Oxford, UK.; Fittall MW; Cancer Institute, University College London, London, UK.; Khan S; University of Leicester, Leicester, UK.; Liu JKH; University of Leeds, Leeds, UK.; Platt JR; Leeds Institute of Medical Research at St James's, Leeds, UK.; Mew R; Torbay and South Devon NHS Foundation Trust, Torquay, UK.; Tripathy AR; Queen Elizabeth Hospital Birmingham, Birmingham, UK.; Watts I; Royal Free London NHS Foundation Trust, London, UK.; Williams ST; University of Sheffield, Sheffield, UK.; Appanna N; Oxford Medical School, University of Oxford, Oxford, UK.; Al-Hajji Y; Birmingham Medical School, University of Birmingham, Birmingham, UK.; Barnard M; UK Health Security Agency, London, UK.; Benny L; UK Health Security Agency, London, UK.; Burnett A; Weston Park Cancer Centre, Sheffield, UK.; Bytyci J; Department of Oncology, University of Oxford, Oxford, UK.; Cattell EL; Taunton and Somerset NHS Foundation Trust, Taunton, UK.; Cheng V; University of Leeds, Leeds, UK.; Clark JJ; Imperial College London, London, UK.; Eastlake L; Royal Cornwall Hospital Trust, Truro, UK.; Gerrand K; UK Health Security Agency, London, UK.; Ghafoor Q; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Grumett S; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Harper-Wynne C; Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK.; Kahn R; Blood Cancer UK, London, UK.; Lee AJX; University College London, London, UK.; Lomas O; Oxford University Hospitals NHS Trust, Oxford, UK.; Lydon A; Torbay and South Devon NHS Foundation Trust, Torquay, UK.; Mckenzie H; University Hospital Southampton NHS Foundation Trust, Southampton, UK.; Panneerselvam H; Wye Valley NHS Trust, Hereford, UK.; Pascoe JS; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Patel G; University College London, London, UK.; Patel V; National Health Service, London, UK.; Potter VA; University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.; Randle A; Royal College of Physicians, London, UK.; Rigg AS; Guy's and St Thomas' NHS Foundation Trust, London, UK.; Robinson TM; University of Bristol, Bristol, UK.; Roylance R; University College London Hospitals NHS Foundation Trust, London, UK.; Roques TW; Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.; Rozmanowski S; UK Health Security Agency, London, UK.; Roux RL; Oxford University Hospitals NHS Trust, Oxford, UK.; Shah K; Oxford University Hospitals NHS Trust, Oxford, UK.; Sheehan R; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.; Sintler M; Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK.; Swarup S; Department of Oncology, University of Oxford, Oxford, UK.; Taylor H; Oxford Medical School, University of Oxford, Oxford, UK.; Tillett T; Royal United Hospital Bath NHS Trust, Bath, UK.; Tuthill M; Oxford University Hospitals NHS Trust, Oxford, UK.; Williams S; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Ying Y; Department of Oncology, University of Oxford, Oxford, UK.; Beggs A; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.; Iveson T; University Hospital Southampton NHS Foundation Trust, Southampton, UK.; Lee SM; University College London Hospitals NHS Foundation Trust, London, UK.; Middleton G; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.; Middleton M; Department of Oncology, University of Oxford, Oxford, UK.; Protheroe A; Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; Fowler T; UK Health Security Agency, London, UK.; William Harvey Research Institute, London, UK.; Johnson P; University of Southampton, Southampton, UK.; Lee LYW; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. lennard.lee@oncology.ox.ac.uk.; Department of Oncology, University of Oxford, Oxford, UK. lennard.lee@oncology.ox.ac.uk.
Source
Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
Subject
Language
English
Abstract
Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.
(© 2023. The Author(s).)